Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine

Alexander Hirst, Chris Knight, Matt Hirst, Will Dunlop () and Ron Akehurst

The European Journal of Health Economics, 2016, vol. 17, issue 2, 217-227

Abstract: Transdermal buprenorphine is cost-effective compared to tramadol at a willingness-to-pay threshold of £20,000 per QALY. Copyright The Author(s) 2016

Keywords: Tramadol; Fractures; Pain; Elderly; Buprenorphine; Cost-effectiveness (search for similar items in EconPapers)
Date: 2016
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-015-0673-1 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:17:y:2016:i:2:p:217-227

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-015-0673-1

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().